Halozyme Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 54,799 42,325 56,086 13,624
Cost of Revenue 6,246 1,094 258 985
Gross Profit 48,554 41,231 55,829 12,639
Operating Expenses
Research and Development 96,640 70,044 57,563 51,774
Sales, General and Admin. 32,348 24,812 18,104 15,123
Non-Recurring Items - - - -
Other - - - -
Operating Income (80,434) (53,625) (19,839) (54,258)
Income From Continuing Operations
Add'l Income/Expense Items 229 73 69 1,016
Earnings Before Interest and Tax (80,204) (53,552) (19,770) (53,242)
Interest Expense 3,274 - - -
Earnings Before Tax (83,479) (53,552) (19,770) (53,242)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (83,479) (53,552) (19,770) (53,242)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (83,479) (53,552) (19,770) (53,242)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (83,479) (53,552) (19,770) (53,242)